Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC1652849807;49808;49809 chr2:178613227;178613226;178613225chr2:179477954;179477953;179477952
N2AB1488744884;44885;44886 chr2:178613227;178613226;178613225chr2:179477954;179477953;179477952
N2A1396042103;42104;42105 chr2:178613227;178613226;178613225chr2:179477954;179477953;179477952
N2B746322612;22613;22614 chr2:178613227;178613226;178613225chr2:179477954;179477953;179477952
Novex-1758822987;22988;22989 chr2:178613227;178613226;178613225chr2:179477954;179477953;179477952
Novex-2765523188;23189;23190 chr2:178613227;178613226;178613225chr2:179477954;179477953;179477952
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: E
  • RefSeq wild type transcript codon: GAA
  • RefSeq wild type template codon: CTT
  • Domain: Fn3-7
  • Domain position: 79
  • Structural Position: 111
  • Q(SASA): 0.2148
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
E/K None None 0.999 N 0.485 0.396 0.349204839081 gnomAD-4.0.0 6.85133E-07 None None None None N None 0 0 None 0 0 None 0 0 9.00126E-07 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
E/A 0.8555 likely_pathogenic 0.7339 pathogenic -1.167 Destabilizing 0.999 D 0.638 neutral N 0.464062798 None None N
E/C 0.99 likely_pathogenic 0.9719 pathogenic -0.933 Destabilizing 1.0 D 0.85 deleterious None None None None N
E/D 0.9099 likely_pathogenic 0.8775 pathogenic -1.506 Destabilizing 0.999 D 0.462 neutral D 0.614839725 None None N
E/F 0.995 likely_pathogenic 0.9836 pathogenic -1.24 Destabilizing 1.0 D 0.882 deleterious None None None None N
E/G 0.925 likely_pathogenic 0.8859 pathogenic -1.535 Destabilizing 1.0 D 0.743 deleterious D 0.584425016 None None N
E/H 0.9846 likely_pathogenic 0.9613 pathogenic -1.498 Destabilizing 1.0 D 0.649 neutral None None None None N
E/I 0.9088 likely_pathogenic 0.7197 pathogenic -0.146 Destabilizing 1.0 D 0.879 deleterious None None None None N
E/K 0.8895 likely_pathogenic 0.7488 pathogenic -1.444 Destabilizing 0.999 D 0.485 neutral N 0.470729637 None None N
E/L 0.9634 likely_pathogenic 0.8762 pathogenic -0.146 Destabilizing 1.0 D 0.839 deleterious None None None None N
E/M 0.9466 likely_pathogenic 0.8191 pathogenic 0.471 Stabilizing 1.0 D 0.833 deleterious None None None None N
E/N 0.9722 likely_pathogenic 0.9469 pathogenic -1.665 Destabilizing 1.0 D 0.675 prob.neutral None None None None N
E/P 0.9996 likely_pathogenic 0.9992 pathogenic -0.468 Destabilizing 1.0 D 0.777 deleterious None None None None N
E/Q 0.6555 likely_pathogenic 0.4704 ambiguous -1.41 Destabilizing 1.0 D 0.587 neutral N 0.475521385 None None N
E/R 0.9446 likely_pathogenic 0.882 pathogenic -1.392 Destabilizing 1.0 D 0.677 prob.neutral None None None None N
E/S 0.9089 likely_pathogenic 0.8477 pathogenic -2.217 Highly Destabilizing 0.999 D 0.518 neutral None None None None N
E/T 0.9191 likely_pathogenic 0.8257 pathogenic -1.881 Destabilizing 1.0 D 0.775 deleterious None None None None N
E/V 0.7947 likely_pathogenic 0.5381 ambiguous -0.468 Destabilizing 1.0 D 0.802 deleterious N 0.441534686 None None N
E/W 0.9985 likely_pathogenic 0.9956 pathogenic -1.407 Destabilizing 1.0 D 0.851 deleterious None None None None N
E/Y 0.9926 likely_pathogenic 0.9767 pathogenic -1.111 Destabilizing 1.0 D 0.84 deleterious None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.